Chronic, low-grade, systemic inflammation that characterizes primary hypertension may influence changes in the expression level of IGFBP-binding proteins, which may limit the bioavailability of IGF-1, change the IGF-1/IGF-1R signaling, and IGF-1R receptor resistance to IGF-1 binding. This evidence concerns the gene IGF1R and essential hypertension.